NASDAQ:MDWD
MediWound Ltd. Stock News
$17.71
-0.0400 (-0.225%)
At Close: May 09, 2024
MediWound to Present at Cowen and Company 40th Annual Healthcare Conference
09:18pm, Friday, 28'th Feb 2020
YAVNE, Israel, Feb. 28, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.
The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
12:28pm, Friday, 28'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on Feb. 27)
Global Cord Blood Corp (...
MediWound to Present at Cowen and Company 4…th Annual Healthcare Conference
12:00am, Friday, 28'th Feb 2020
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fat
Organogenesis: Undervalued And Promising Investment Opportunity For 2020
09:37am, Thursday, 27'th Feb 2020
Puraply is a key growth driver of Organogenesis’ advanced wound care business. There are multiple short-term, mid-term, and long-term growth catalysts for the c
Vericel Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Full-Year 2020 Financial Guidance
01:00pm, Tuesday, 25'th Feb 2020
Full Year 2019 Product Revenues of $117.9 Million Increased 30% Over 2018 Record Quarterly Revenue and Profit in the Fourth Quarter Conference Call Today at.
MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results
12:00pm, Tuesday, 25'th Feb 2020
Generated total full-year 2019 revenues of $31.8 million, driven primarily by Vericel license payment and development services to BARDA Initiated U.S. Phase 2 adaptive design.
MediWound Q4 EPS $(0.13) Misses $(0.1) Estimate, Sales $5.442M Beat $4.08M Estimate
12:00am, Tuesday, 25'th Feb 2020Vericel to Present at the 40th Annual Cowen Healthcare Conference on Monday, March 2, 2020
03:04pm, Monday, 24'th Feb 2020
CAMBRIDGE, Mass., Feb. 24, 2020 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that.
MediWound to Report Fourth Quarter & Fiscal 2019 Financial Results and Host a Conference Call and Webcast on February 25, 2020
01:00pm, Tuesday, 18'th Feb 2020
YAVNE, Israel, Feb. 18, 2020 -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn.
MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
01:00pm, Monday, 13'th Jan 2020
MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its agree
MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
12:00am, Monday, 13'th Jan 2020BARDA Initiates the Procurement of NexoBrid for Emergency Response
11:30am, Monday, 06'th Jan 2020
MediWound Ltd. (MDWD) and its U.S. commercial partner Vericel Corporation (VCEL) today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Assistant Secre
